HREC Approves Comparator Study for Pivotal Phase 3 DFI
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The amendment introduces a new randomized, active-controlled study arm, allowing for a head-to-head comparison against existing antibiotics used for treating these infections. Patient recruitment and treatment are ongoing, with the study designed to enhance the depth of efficacy data collected during the trial.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Vietnamese Patent Granted for RECCE Anti-Infectives
- AUD $3.7M Income Tax Refund Received
- Placement & SPP to raise $8 million
- HREC Approval Accelerates Global Phase 3 DFI Strategy
- Addendum to Recce Signs Middle East Licensing Term Sheet
Later from Recce Pharmaceuticals
- Appendix 4E and FY26 Annual Report
- Amendments to Debt Facility with Avenue Capital Group
- Independent Review of Indonesian Phase 3 R327G Trial Data
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals